comorbidities in people aging with HIV
Conditions
Interventions
Het screeningsprtocol zal geïmplementeerd worden in de HIV-polikliniek in het AMC en zal zoveel mogelijk worden geïntegreerd in de reguliere polikliniek. Gedurende een routine bezoek aan de poliklinie
Sponsors
Amsterdam UMC
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Provide written informed consent 2. AMC: HIV-1 infected patients , age 45 years and older 3. GGD: HIV-negative persons, age 45 years and older 4. Additional inclusion criteria needed to be fullfilled to participate in the substudy 1: Central Nervous System which was completed sometime ago, for detailed information see chapter 3.3 of the clinical study protocol of this substudy.
Exclusion criteria
Exclusion criteria: 1. GGD: HIV-positive persons 2. Additional exclusion criteria were applicable for participation in the substudie 1: Central Nervous System which was completed sometime ago; for detailed information on these additional exclusion criteria see chapter 3.4 of the clinical study protocol of this substudy 1
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1A) the screeningsprotocol 1B) the prevalence and incidence of co-morbidity and organ system dysfunction in the setting of HIV infection and the comparison with the prevalence of comorbidity in a comparable group of HIV-uninfected healthy individuals. 1C) the difference in quality of life both at baseline and over time, between patients with and without co-morbidity, who are HIV-infected or HIV-uninfected. 2A) Correlation between cognitive test performance scores and neuroimaging parameters e.g. DTI (mean diffusivity, fractional diffusivity), MRS (concentrations of glutamate, N-acetylaspartate, choline and myo-inositol) and ASL (cerebral blood perfusion) in HIV-infected persons with sustained suppression of HIV-infection on cART compared to HIV-negative controls. 2B) Correlation between cerebrospinal fluid/blood markers (virological-, host response- and CNS tissue damage markers) and neuroimaging parameters of cognitive impairment in HIV-infected persons with sustained suppression of HIV-infection on cART compared to HIV-negative controls. 2C) Correlation between markers of retinal abnormalities as measured by optical coherence tomography and neuroimaging parameters of cognitive impairment and cerebrospinal markers in HIV-infected persons with sustained suppression of HIV-infection on cART compared to HIV-negative controls. 2D) The predictive value of each assessed neuroimaging parameter of subtle brain changes or a combination of such parameters, for cognitive impairment in older HIV-1-infected persons with sustained viral suppression on cART. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) N/A 2A) Prevalence and incidence of cognitive impairment in older HIV-1-infected persons with sustained viral suppression on combined antiretroviral therapy (cART) compared to HIV-negative controls. 2B) How demographic characteristics (e.g. age, gender, ethnicity), behavioural factors (e.g. alcohol and drug abuse), psychological factors (major depression, anxiety disorders) and co-morbidities (e.g. hypertension, diabetes mellitus-type II, dyslipidemia, chronic viral hepatitis) are related to HAND/neurocognitive disorders and retinal abnormalities found in HIV-infected- and HIV-negative elderly. | — |
Countries
Netherlands
Contacts
Public ContactM. van der Valk
Amsterdam UMC
Outcome results
None listed